Bilypsa Tablet
Prescription Required
Marketer
Zydus Cadila
SALT COMPOSITION
Saroglitazar (4mg)
Storage
Store below 30°C
Click here to view all substitutes
Buynow
Product Introduction
Bilypsa Tablet contains saroglitazar, a groundbreaking dual PPAR α/γ agonist that represents a significant advancement in treating complex metabolic disorders. This innovative medication addresses multiple aspects of metabolic dysfunction simultaneously, making it particularly valuable for patients with comorbid conditions. Developed after extensive research, saroglitazar 4mg offers a unique therapeutic approach by targeting both lipid abnormalities and insulin resistance through its dual mechanism of action.
Saroglitazar, the active ingredient in Bilypsa, holds the distinction of being the world's first approved dual PPAR α/γ agonist. This pharmaceutical innovation originated from India and has steadily gained recognition globally for its efficacy in managing dyslipidemia associated with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The 4mg dosage strength represents the standard therapeutic dose, carefully calibrated to provide optimal benefits while minimizing potential side effects.
Patients with diabetic dyslipidemia often struggle with a challenging combination of elevated triglycerides, low HDL cholesterol, and insulin resistance. Traditional treatments frequently address only individual components of this metabolic triad, necessitating multiple medications. Bilypsa's dual action helps streamline therapy by targeting these related metabolic abnormalities with a single agent, potentially improving both treatment adherence and outcomes.
The liver-directed activity of saroglitazar makes it particularly beneficial for patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease lacking effective pharmacological treatments until recently. By reducing liver fat accumulation and improving insulin sensitivity in liver cells, Bilypsa addresses the underlying pathophysiology of NASH, potentially slowing disease progression and reducing the risk of complications like cirrhosis.
Healthcare providers value Bilypsa for its demonstrated efficacy in reducing triglycerides, improving glycemic parameters, and its favorable safety profile with minimal weight gain effects compared to other insulin sensitizers. The once-daily oral dosing further enhances convenience and potentially improves medication adherence for patients who may already be taking multiple medications for metabolic conditions.
While still relatively new to the therapeutic landscape, saroglitazar represents an important addition to the pharmaceutical options available for managing the complex interrelated aspects of metabolic syndrome, type 2 diabetes, and fatty liver disease. As with any medication, Bilypsa should be used as part of a comprehensive treatment approach that includes appropriate lifestyle modifications and regular monitoring of metabolic parameters.
Key Composition & Ingredients
- Active Ingredient: Saroglitazar 4mg
- Inactive Ingredients: Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, and other pharmaceutical excipients
Uses of Bilypsa Tablet
- Treatment of diabetic dyslipidemia in type 2 diabetes mellitus patients
- Management of hypertriglyceridemia in patients with type 2 diabetes
- Adjunct therapy for improving glycemic control in type 2 diabetes
- Treatment of non-alcoholic fatty liver disease (NAFLD)
- Management of non-alcoholic steatohepatitis (NASH)
- Reduction of elevated triglyceride levels in patients with metabolic syndrome
- Improvement of lipid parameters in patients with insulin resistance
- Adjunctive therapy in patients with persistent hypertriglyceridemia despite statin therapy
- Management of primary hypertriglyceridemia in specific patient populations
- Reduction of liver fat content in patients with hepatic steatosis
Benefits of Bilypsa Tablet
- Dual action on lipid metabolism and insulin resistance
- Significant reduction in triglyceride levels
- Improvement in HDL cholesterol (good cholesterol) levels
- Reduction in non-HDL cholesterol levels
- Improvement in liver function tests in patients with fatty liver
- Enhanced glycemic control in diabetic patients
- Reduction in liver fat content in NAFLD/NASH
- Minimal effect on body weight compared to other insulin sensitizers
- Convenience of once-daily dosing
- Potential for reducing the need for multiple medications
- May help slow progression of fatty liver disease
- Improvement in markers of insulin resistance
How Bilypsa Tablet Works (Mechanism of Action)
Saroglitazar, the active ingredient in Bilypsa, works through a dual mechanism as a PPAR α/γ agonist:
- PPAR-α Activation (Predominant Effect):
- Increases expression of enzymes involved in fatty acid oxidation
- Enhances breakdown of triglycerides in the liver
- Reduces production of very low-density lipoproteins (VLDL)
- Increases production of apolipoprotein A-I and A-II, raising HDL levels
- Decreases hepatic triglyceride synthesis
- Enhances expression of fatty acid transport proteins
- PPAR-γ Activation (Moderate Effect):
- Improves insulin sensitivity in peripheral tissues
- Enhances glucose uptake by adipose tissue and skeletal muscles
- Reduces free fatty acid levels in circulation
- Modulates adipokine production (increased adiponectin, decreased TNF-α)
- Decreases hepatic gluconeogenesis
- Reduces inflammation in liver and adipose tissue
Through this balanced dual action, saroglitazar addresses multiple aspects of metabolic dysfunction, particularly focusing on improving lipid parameters while providing moderate insulin-sensitizing effects.
Dosage of Bilypsa Tablet
Daily Dose
- Standard dosage: 4mg once daily
- Initial therapy: 4mg once daily with or without food
- Maintenance dose: Continued at 4mg once daily with periodic assessment of response
- Maximum dose: 4mg daily (higher doses not recommended)
- Duration: Long-term therapy as determined by physician based on clinical response
Missed Dose
- Take as soon as remembered if within the same day
- Skip the missed dose if it's already time for the next scheduled dose
- Do not take double doses to compensate for missed doses
- Return to regular dosing schedule the next day
- Consult healthcare provider if multiple doses are missed
Overdose
- Limited data available on overdose
- Seek immediate medical attention if overdose is suspected
- Supportive care based on symptoms
- Monitor liver function, blood glucose, and lipid levels
- No specific antidote is known
How to Use Bilypsa Tablet
- Take exactly as prescribed by your healthcare provider
- Swallow the tablet whole with a glass of water
- Can be taken with or without food
- Take at approximately the same time each day
- Do not crush, split, or chew the tablet
- Continue taking even if you feel well
- Regular monitoring of lipid levels and liver function is recommended
- Follow dietary recommendations and exercise plan as advised
- Store at room temperature away from moisture and heat
- Keep out of reach of children
Side Effects of Bilypsa Tablet
Common Side Effects
- Dyspepsia (indigestion)
- Mild gastric discomfort
- Headache
- Fatigue
- Asthenia (weakness)
- Back pain
- Transient elevation in liver enzymes
- Mild edema (swelling)
Serious Side Effects (Require Immediate Medical Attention)
- Significant elevation in liver enzymes
- Signs of liver dysfunction (yellowing of skin/eyes, dark urine, abdominal pain)
- Severe allergic reactions (rash, itching, swelling, severe dizziness)
- Unexplained muscle pain, tenderness, or weakness
- Persistent stomach/abdominal pain
- Symptoms of pancreatitis (severe abdominal pain radiating to back, nausea, vomiting)
- Unusual weight gain or edema
How to Manage Side Effects
- For gastric discomfort: Take with food, avoid spicy or greasy meals
- For headache: Over-the-counter pain relievers as approved by doctor
- For fatigue: Adequate rest, proper hydration, balanced diet
- Monitor liver function tests as recommended by physician
- Report persistent or severe side effects to healthcare provider promptly
- Do not self-medicate for side effects without consulting doctor
Safety Advice for Bilypsa Tablet
Alcohol
- CAUTION: May worsen liver function; limit or avoid consumption
Pregnancy
- UNSAFE: Not recommended during pregnancy; discuss with doctor
Breastfeeding
- UNSAFE: Not recommended during breastfeeding; alternative feeding advised
Driving
- SAFE: No known effects on ability to drive or operate machinery
Kidney
- CAUTION: Use with caution in severe kidney impairment; monitor function
Liver
- CAUTION: Monitor liver function; contraindicated in active liver disease
Children
- NOT RECOMMENDED: Safety and efficacy not established in pediatric population
Older Patients
- SAFE IF PRESCRIBED: No specific dose adjustment needed; monitor closely
Allergy
- AVOID: Do not use if allergic to saroglitazar or any ingredients in Bilypsa
Warnings & Precautions for Bilypsa Tablet
- Not recommended in patients with active liver disease or unexplained persistent elevations in liver enzymes
- Regular monitoring of liver function is advised
- Use with caution in patients with history of gallbladder disease
- Not studied in combination with fibrates; concurrent use not recommended
- Limited data in severe renal impairment; use with caution
- Not indicated for type 1 diabetes mellitus
- Not a substitute for insulin in insulin-requiring patients
- Potential for fluid retention; use with caution in heart failure
- Monitor for weight gain and edema, especially in patients with cardiovascular risks
- Effects on cardiovascular outcomes not fully established
- May potentially interact with drugs metabolized by certain CYP enzymes
- Not recommended in patients with history of PPAR agonist hypersensitivity
Interactions with Bilypsa Tablet
Drug-Drug Interactions
- Fibrates: Concurrent use not recommended due to similar mechanism
- Statins: Generally safe to use together; monitor for muscle-related side effects
- Anti-diabetic medications: May enhance hypoglycemic effects; monitor blood glucose
- CYP3A4 inhibitors: May increase saroglitazar levels; monitor for increased side effects
- CYP3A4 inducers: May decrease efficacy; dose adjustment may be needed
- Warfarin and other anticoagulants: Monitor INR due to potential interactions
- Bile acid sequestrants: Separate administration by at least 2 hours
- Cyclosporine: Potential for increased exposure; monitor cyclosporine levels
Drug-Food Interactions
- Can be taken with or without food
- No significant food interactions reported
- High-fat meals may slightly delay absorption but do not significantly affect overall bioavailability
Contraindications of Bilypsa Tablet
- Active liver disease or unexplained persistent elevations of serum transaminases
- Known hypersensitivity to saroglitazar or any component of the formulation
- Pregnancy and breastfeeding
- Severe renal impairment (eGFR <30 mL/min/1.73m²)
- Congestive heart failure (NYHA Class III-IV)
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Active gallbladder disease
- Concurrent use with other PPAR agonists (thiazolidinediones, fibrates)
- Severe hepatic impairment (Child-Pugh C)
Diet & Lifestyle Advice
- Follow a heart-healthy diet low in saturated fats and trans fats
- Limit intake of refined carbohydrates and sugary foods
- Increase consumption of fiber-rich foods (whole grains, fruits, vegetables)
- Maintain a healthy weight; aim for gradual weight loss if overweight
- Engage in regular physical activity (at least 150 minutes of moderate exercise weekly)
- Limit alcohol consumption
- Avoid smoking
- Monitor blood glucose regularly if diabetic
- Stay well-hydrated
- Follow a consistent eating schedule
- Reduce sodium intake to help manage blood pressure
- Consider Mediterranean diet pattern which benefits both liver health and metabolic parameters
Why Doctors Recommend This Medicine
Doctors prescribe Bilypsa because:
- It uniquely addresses both lipid abnormalities and insulin resistance
- It effectively reduces triglycerides, a major risk factor for pancreatitis
- It improves glycemic control in type 2 diabetes
- It has beneficial effects on fatty liver disease, which lacks many treatment options
- It offers once-daily convenient dosing
- It has minimal weight gain compared to other insulin sensitizers like thiazolidinediones
- It may reduce the need for multiple medications for managing diabetic dyslipidemia
- It has a favorable safety profile in clinical studies
- It targets multiple components of metabolic syndrome
- It addresses non-HDL cholesterol, an important cardiovascular risk marker
Substitutes of Bilypsa Tablet & Alternative Medicines
- For Triglyceride Reduction:
- Fibrates (fenofibrate, gemfibrozil)
- Omega-3 fatty acids/fish oil supplements
- Niacin (nicotinic acid)
- For Glycemic Control:
- Metformin
- Sulfonylureas
- DPP-4 inhibitors
- SGLT-2 inhibitors
- GLP-1 receptor agonists
- Thiazolidinediones (pioglitazone, rosiglitazone)
- For NAFLD/NASH:
- Vitamin E
- Pioglitazone
- Liraglutide and other GLP-1 receptor agonists
- Ursodeoxycholic acid (off-label)
Storage Guidelines
- Store at room temperature between 15°C to 30°C (59°F to 86°F)
- Keep away from direct sunlight, heat, and moisture
- Store in the original container with the lid tightly closed
- Keep out of reach of children
- Do not store in bathroom or kitchen where humidity is high
- Do not freeze
- Check expiration date before using
- Do not use if the tablet appearance has changed
- Dispose of expired medication properly
- Do not remove from original packaging until ready to take
Quick Tips for Bilypsa Tablet
- Take at the same time each day to maintain consistent blood levels
- Regular monitoring of lipid profile helps track effectiveness
- Continue medication even when feeling well
- Report any unusual symptoms to your doctor promptly
- Periodic liver function tests are important during treatment
- Combining with lifestyle changes enhances effectiveness
- Inform all healthcare providers about this medication
- Carry information about this medication when traveling
- Do not stop taking abruptly without consulting your doctor
- Keep follow-up appointments to monitor progress
- Remember that full benefits may take several weeks to develop
- This medication treats but does not cure underlying conditions
Fact Box
- Chemical Class: Dual PPAR α/γ agonist
- Habit Forming: No
- Therapeutic Class: Anti-dyslipidemic and anti-diabetic agent
- Action Class: PPAR (Peroxisome Proliferator-Activated Receptor) agonist
Useful Diagnostic Tests
- Lipid profile (total cholesterol, HDL, LDL, triglycerides)
- Liver function tests (ALT, AST, bilirubin)
- Fasting blood glucose
- HbA1c (glycated hemoglobin)
- Kidney function tests (serum creatinine, eGFR)
- Liver ultrasound or FibroScan (for NAFLD/NASH patients)
- HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
- Adiponectin levels (research setting)
- Liver stiffness measurements (in NASH patients)
- Complete blood count
More Information & References
For additional information about Bilypsa (Saroglitazar), consult:
- Your healthcare provider or pharmacist
- Clinical practice guidelines for dyslipidemia management
- NAFLD/NASH treatment guidelines
- Diabetes management resources
- Product information leaflet
- Regulatory authorities' medication databases
- Medical literature on dual PPAR agonists
Disclaimer
This information is intended for educational purposes only and does not replace professional medical advice. Always consult with your healthcare provider regarding any medical conditions and before starting, stopping, or changing any medication regimen. Individual results may vary, and all potential risks and benefits should be discussed with your healthcare provider. This medication should only be used under proper medical supervision.
"Bilypsa Tablet – For diabetes, fatty liver, and high cholesterol management. Available online at RXDawa."
Bilypsa Tablet – Diabetes & Fatty Liver Treatment | Buy Online at RXDawa